Press releases
- Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
- AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
- CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
- CareDx to Participate in Upcoming Investor Conferences
- Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
- CareDx Reports First Quarter 2024 Results
- CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- CareDx to Report First Quarter 2024 Financial Results
- CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
More ▼
Key statistics
On Friday, CareDx Inc (1K9:DUS) closed at 14.00, -10.34% below its 52-week high of 15.62, set on May 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.02 |
---|---|
High | 14.08 |
Low | 13.99 |
Bid | 14.03 |
Offer | 14.16 |
Previous close | 14.01 |
Average volume | 0.00 |
---|---|
Shares outstanding | 52.08m |
Free float | 50.30m |
P/E (TTM) | -- |
Market cap | 759.90m USD |
EPS (TTM) | -3.43 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 18:30 BST.
More ▼